首页|卵巢癌生物标志物研究进展

卵巢癌生物标志物研究进展

扫码查看
卵巢癌是最常见的女性生殖系统恶性肿瘤之一,死亡率居妇科恶性肿瘤之首.由于发病初期缺乏特异性症状,并且肿瘤异质性高,卵巢癌的早期诊断、疗效监测和预后评估成为临床面临的三大难题.近年来,越来越多的研究开始关注卵巢癌生物标志物,旨在推动精准医疗的发展.本文将综合探讨卵巢癌生物标志物在辅助诊断、治疗响应预测和预后评估等方面的研究现状,以期为卵巢癌患者制定个体化的临床决策提供参考.
Advances in biomarkers for ovarian cancer
Ovarian cancer is one of the most prevalent malignancies of the female reproductive system,and its mortality rate ranks first among gynecological malignant tumors.Due to the lack of specific symptoms in the early stage of the disease and the high heterogeneity of tumors,early diagnosis,therapeutic efficacy monitoring,and prognosis prediction of ovarian cancer have become three major challenges in clinical practice.In recent years,an increasing number of studies have focused on exploring biomarkers for ovarian cancer,intending to advance the field of precision medicine.This article aims to provide a comprehensive review of ovarian cancer biomarkers about auxiliary diagnosis,treatment response prediction,and prognosis evaluation,with the hope of offering valuable insights for individualized clinical de-cision-making for ovarian cancer patients.

ovarian cancerbiomarkerprecision medicine

焦笑飞、高庆蕾

展开 >

华中科技大学同济医学院附属同济医院妇科肿瘤科,湖北 武汉 430030

卵巢癌 生物标志物 精准医疗

2024

实用肿瘤杂志
浙江大学

实用肿瘤杂志

CSTPCD
影响因子:1.034
ISSN:1001-1692
年,卷(期):2024.39(5)